Drugs / Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06131554 | Mar → Jul 2024 overdue | meningococcal meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07374510 Comparator | Jan → Sep 2026 expected | meningococcal meningitis | Sinovac Life Sciences Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07710872 Comparator | Aug 2026 → Mar 2028 expected | meningococcal infection | Sanofi | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07505823 Comparator | Mar 2026 → Apr 2027 expected | meningitis, meningococcal infection | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) | “Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)” NCT07505823 ↗ |
| Known as | Menhycia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710872 ↗ |
| Modality | Vaccine | “Meningococcal Conjugate Vaccine” NCT06131554 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06131554 ↗ |